Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study
| Autor: | Hugo Rotkopf, Farida Mesli, Francesco Brunetti, Jenny Tannoury, Nicolas Petitdidier, Nicola de’Angelis, Charlotte Gagniere, Iradj Sobhani, Aurelien Amiot, Anne Hulin |
|---|---|
| Přispěvatelé: | Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty [SDV]Life Sciences [q-bio] Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Crohn Disease Gastrointestinal Agents Maintenance therapy Internal medicine medicine Humans In patient Patient Reported Outcome Measures Prospective Studies 10. No inequality Prospective cohort study Biosimilar Pharmaceuticals Crohn's disease Hepatology Drug Substitution business.industry Remission Induction Gastroenterology Antibodies Monoclonal Biosimilar Middle Aged medicine.disease Ulcerative colitis Infliximab 3. Good health 030220 oncology & carcinogenesis Colitis Ulcerative Female 030211 gastroenterology & hepatology France Drug Monitoring business medicine.drug |
| Zdroj: | Digestive and Liver Disease Digestive and Liver Disease, WB Saunders, 2019, 51, pp.1652-1660. ⟨10.1016/j.dld.2019.08.020⟩ Digestive and Liver Disease, Elsevier, 2019, 51, pp.1652-1660. ⟨10.1016/j.dld.2019.08.020⟩ |
| ISSN: | 1590-8658 |
| Popis: | Background Patients’ perspectives after switching from infliximab to a biosimilar have yet to be assessed. Aim To assess patients’ perspectives in a prospective manner after switching from infliximab to CT-P13. Methods 113 consecutive patients with inflammatory bowel disease (IBD) on maintenance therapy with infliximab were switched to CT-P13. Patients’ perspectives were assessed by questionnaires, including the Beliefs about Medicines Questionnaire (BMQ) and FACIT-F (questionnaire regarding fatigue), and patient-reported outcomes (IBD disability index) at the inclusion and after the fourth CT-P13 infusion. Results After one year, the patients’ perspectives did not change after the switch according to BMQ-general, BMQ-specific necessity and BMQ-specific concerns subscales. No difference was observed in the mean IBD-DI score, while a significant improvement in fatigue was observed according to the FACIT-F questionnaire. Patients’ concerns were raised about the use of biosimilars and the risks of switching with a significant improvement after switching (65% vs. 42%, respectively, p = 0.01). Fourteen (12.4%) patients experienced loss of response to CT-P13, including 12 with restoration of steroid-free clinical remission after CT-P13 dose optimization. Conclusion Although some concerns were reported, no difference was observed in patients’ perspectives after switching from infliximab to CT-P13. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect